A Gut Bacteria Fat Molecule Flips On a Liver Switch Tied to Diabetes

If you have ever wondered how something as small as a gut microbe could reach all the way into your liver, a newly published study offers one of the clearest chemical answers yet. Researchers identified a fat molecule made by several gut bacteria, including a well-studied probiotic strain, that binds directly to a liver protein controlling blood sugar and fat production. In obese, high-blood-sugar mice, dosing them with this bacterial fat improved glucose control and eased fatty liver disease, tracing a direct chemical line from a single bacterial metabolite to a specific molecular switch inside liver cells.

Key takeaways

• Several gut bacteria, including the probiotic strain B420, produce a fat called vaccenic acid that directly binds and switches on LRH-1, a liver protein that helps control blood sugar and fat production.
• In obese, high-fat-diet mice, two weeks of vaccenic acid injections lowered blood glucose, reduced serum insulin, and improved a standard fatty-liver damage score, largely by shutting down genes the liver uses to manufacture new fat.
• Vaccenic acid already occurs naturally in meat, dairy, and the gut microbiome, and separate human data cited in the paper links higher circulating vaccenic acid to lower type 2 diabetes risk.
• Caveat: this is animal and cell-based mechanism research using injections rather than diet, tested only in male mice, not yet studied in humans, and one coauthor has a disclosed industry tie to the probiotic's supplier.

Vaccenic Acid Activates the Liver's LRH-1 Receptor

Researchers, publishing in EMBO Molecular Medicine, discovered that vaccenic acid (VA), a fat molecule produced by several species of gut bacteria, directly switches on Liver Receptor Homolog-1 (LRH-1, also known as NR5A2), a protein found in liver, intestinal, and pancreatic cells that helps regulate blood sugar, fat production, and bile acid levels. The team first noticed that lipid extracts from the probiotic strain Bifidobacterium animalis subsp. lactis B420 strongly activated LRH-1 in human cells engineered to overexpress the receptor. Chasing that signal through repeated rounds of chemical purification, they narrowed the active ingredient down to a single compound and identified it, using nuclear magnetic resonance and mass spectrometry, as vaccenic acid, a monounsaturated 18-carbon fat that exists in cis and trans forms. Using a binding technique called microscale thermophoresis on purified LRH-1 protein, they confirmed vaccenic acid physically docks into the receptor's ligand-binding pocket, with the cis form binding roughly ten times more tightly (dissociation constant of 14.2 micromolar) than the trans form (144.4 micromolar). Closely related fats, including oleic acid and linoleic acid, did not bind or activate the receptor at all, showing the effect is specific to vaccenic acid's exact chemical shape rather than a generic fat effect. LRH-1 has long been classified as an "orphan" nuclear receptor because no confirmed naturally occurring activator had been identified; this study proposes vaccenic acid as exactly that missing piece.

Why This Matters for Fatty Liver Disease and Diabetes Risk

This finding lands squarely in territory that matters to anyone managing, or worried about, non-alcoholic fatty liver disease (NAFLD, increasingly called MAFLD, for metabolic-associated fatty liver disease) or type 2 diabetes. LRH-1 is not just a laboratory curiosity: the paper notes that disrupted LRH-1 activity has already been linked to type 2 diabetes, NAFLD/MAFLD, inflammatory bowel disease (IBD), and certain cancers, making it an actively studied drug target. The broader context is the growing recognition that gut bacteria talk to the liver through molecules absorbed into the bloodstream, not just through digestion, a relationship researchers call the gut-liver axis. Because vaccenic acid is a common part of the human diet, found naturally in meat and dairy fat such as butter, and now shown to be produced by gut bacteria too, its ability to directly engage a metabolic master-switch receptor gives researchers a concrete molecular reason to keep studying dietary fat, the microbiome, and metabolic disease together.

How Researchers Traced One Bacterial Fat to a Specific Receptor

To build this chain of evidence, the team combined cell-based, biochemical, and animal experiments. They first screened lipid extracts from a range of bacteria, including gram-negative and gram-positive commensal and pathogenic species such as E. coli, Klebsiella pneumoniae, and Vibrio cholerae, and found that nearly all of them activated LRH-1 to some degree, with the cis form of vaccenic acid detectable in every strain tested and the trans form found specifically in B420. To test whether vaccenic acid mattered in a living animal, they fed male mice a high-fat diet (45 percent of calories from fat) for 15 weeks, which reliably made the mice obese with high blood glucose, elevated liver enzymes, and visible fatty liver, compared with mice on a standard diet. After 15 weeks, both diet groups received daily injections of vaccenic acid (50 milligrams per kilogram) or an inactive vehicle for two more weeks while continuing their assigned diets.

What the Findings Mean, and Don't Yet Mean, for Diet and Probiotics

In the high-fat-diet mice, vaccenic acid injections lowered blood glucose after 7 and 13 days of treatment and reduced serum insulin levels, and liver tissue analysis showed a significantly improved NAFLD Activity Score, a standard pathology measure of fatty liver severity, driven mainly by less swollen, fat-laden liver cells. At the gene level, RNA sequencing of liver tissue showed that vaccenic acid suppressed several genes the liver uses to manufacture new fat from scratch, a process called de novo lipogenesis, including Fasn, Acacb, and Scd1, which lines up with what has previously been reported for other experimental LRH-1-activating compounds such as DLPC. For a reader managing their own metabolic health, the honest takeaway is that this is not a green light to eat more vaccenic acid or take a specific probiotic expecting these results. The mice received vaccenic acid by injection, not through food, so this study says nothing yet about whether eating more of it, or taking the B420 probiotic strain itself, raises LRH-1 activity the same way in a real digestive system. Separately, the B420 strain used here has already been tested in a randomized controlled trial in overweight adults that found reductions in body fat and waist circumference, though that trial did not measure vaccenic acid or LRH-1 activity directly. What this new study does support is that vaccenic acid, already present in the body from meat and dairy, is worth watching as gut-liver research continues; a large prospective analysis, the Cardiovascular Health Study, separately found that people with higher circulating vaccenic acid had a lower risk of developing type 2 diabetes, consistent with, though independent of, this new mechanism.

What the Study Doesn't Yet Show

Several caveats matter here. The blood glucose improvement at the final treatment day approached but did not clearly cross the researchers' threshold for statistical significance, and vaccenic acid had no significant effect on liver triglyceride levels, cholesterol, or liver scarring (fibrosis) in these mice. The animal experiments used only male mice, so it is unclear whether female mice, or people, would respond the same way. It is also worth being direct about a disclosed industry connection: one coauthor is affiliated with DuPont/IFF, the company (via its Danisco business, which supplied the B420 material used in this research) that has separately studied and commercialized this probiotic strain. That is a disclosed, non-controlling link rather than a reason to dismiss the findings, since the core discovery, that vaccenic acid binds and activates purified LRH-1 protein, was demonstrated independently of B420 using multiple other bacterial species and purified receptor protein in isolation.

What Comes Next

The authors describe their results as opening the door to treating LRH-1-related metabolic disorders through targeted diets, prebiotics, probiotics, or vaccenic-acid-based therapies, but that is a stated future direction, not a current recommendation. The clear next steps are testing oral, dietary-relevant doses of vaccenic acid rather than injections, running the experiment in female mice, and eventually testing whether increasing gut bacterial production of vaccenic acid, or supplementing it directly, changes liver metabolism in humans. No timeline for human testing is given in the paper.

Common Questions

Where does vaccenic acid come from? Vaccenic acid is a fat naturally present in meat and dairy products such as butter, and this study additionally identified it as a byproduct of several species of gut bacteria, including the probiotic Bifidobacterium animalis subsp. lactis B420.

Does this mean a probiotic can treat fatty liver disease or diabetes? Not based on this study. The researchers tested purified vaccenic acid delivered by injection in mice, not the probiotic itself as a treatment, and the work has not been tested in humans.

What is LRH-1 (NR5A2) and why do researchers care about it? LRH-1 is a nuclear receptor protein active in the liver, intestine, and pancreas that helps regulate blood sugar, fat production, and bile acid levels; disrupted LRH-1 activity has been linked to type 2 diabetes, fatty liver disease, inflammatory bowel disease, and some cancers.

Is vaccenic acid the first natural activator discovered for LRH-1? LRH-1 has long been considered an "orphan" receptor without a confirmed natural activator, and the researchers present vaccenic acid as a previously unrecognized one, though earlier work had already identified other lab-made or natural compounds, such as DLPC, that can activate LRH-1 in mice.

References

1. Anna Pia Plazzo, Verena Filz, Michaela Prothiwa, et al. (2026). Microbiome-host communication via vaccenic acid modulates LRH-1/NR5A2 activity and ameliorates metabolic liver disease. EMBO Molecular Medicine. https://doi.org/10.1038/s44321-026-00516-3
2. Jae Man Lee, Yoon Kwang Lee, Jennifer L. Mamrosh, et al. (2011). A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature. https://doi.org/10.1038/nature10111
3. Lotta K. Stenman, Markus J. Lehtinen, Nils Meland, et al. (2016). Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial. EBioMedicine. https://doi.org/10.1016/j.ebiom.2016.10.036
4. Wenjie Ma, Jason HY Wu, Qianyi Wang, et al. (2015). Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study. The American Journal of Clinical Nutrition. https://doi.org/10.3945/ajcn.114.092601